Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial
作者： S. R. Bramhall , A. Rosemurgy , P. D. Brown , C. Bowry , J. A.C. Buckels
DOI: 10.1200/JCO.2001.19.15.3447
关键词: Surgery 、 Pancreatic cancer 、 Oncology 、 Randomized controlled trial 、 Internal medicine 、 Marimastat 、 Pancreatic disease 、 Clinical endpoint 、 Chemotherapy 、 Gemcitabine 、 Survival rate 、 Medicine
摘要: PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study performed to date, compares marimastat, first of a new class agents, with gemcitabine. PATIENTS AND METHODS: Four hundred fourteen patients were receive marimastat 5, 10, or 25 mg bid gemcitabine 1,000 mg/m2. primary end point was survival. Progression-free survival, patient benefit, safety also assessed. RESULTS: There no significant difference between (P = .19). Median times 111, 105, 125, 167 days, respectively, 1-year rates 14%, 20%, 19%, respectively. treated with...
sci-hub.se 参考文章(25)
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 15, pp. 2403- 2413 ,(1997) , 10.1200/JCO.1997.15.6.2403
Harold O. Douglass, Pancreatic cancer: nihilism is obsolete! Pancreas. ,vol. 2, pp. 230- 232 ,(1987) , 10.1097/00006676-198703000-00017
Jian Cao, Akira Shinagawa, Etsuhide Yamamoto, Motoharu Seiki, Hiroshi Sato, Takahisa Takino, Yasunori Okada, A matrix metalloproteinase expressed on the surface of invasive tumour cells Nature. ,vol. 370, pp. 61- 65 ,(1994) , 10.1038/370061A0
Esteve Fernandez, Carlo la Vecchia, Miquel Porta, Eva Negri, Franca Lucchini, Fabio Levi, Trends in pancreatic cancer mortality in Europe, 1955–1989 International Journal of Cancer. ,vol. 57, pp. 786- 792 ,(1994) , 10.1002/IJC.2910570605
Renato G. S. Chirvi, Angela Garofalo, Michael J. Crimmin, Lindsay J. Bawden, Antonella Stoppacciaro, Peter D. Brown, Raffaella Giavazzi, Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor International Journal of Cancer. ,vol. 58, pp. 460- 464 ,(1994) , 10.1002/IJC.2910580326
M Löhr, B Trautmann, M Göttler, S Peters, I Zauner, B Maillet, G Klöppel, Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins British Journal of Cancer. ,vol. 69, pp. 144- 151 ,(1994) , 10.1038/BJC.1994.24
C N Mallinson, M O Rake, J B Cocking, C A Fox, M T Cwynarski, B L Diffey, G A Jackson, J Hanley, V J Wass, Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ. ,vol. 281, pp. 1589- 1591 ,(1980) , 10.1136/BMJ.281.6255.1589
J. Mollenhauer, I. Roether, H. F. Kern, Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas. ,vol. 2, pp. 14- 24 ,(1987) , 10.1097/00006676-198701000-00003
T. M. Gress, F. Müller-Pillasch, M. M. Lerch, H. Friess, M. Büchler, G. Adler, Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. International Journal of Cancer. ,vol. 62, pp. 407- 413 ,(1995) , 10.1002/IJC.2910620409
Anna Maria Storniolo, Nathan H. Enas, Cheryl A. Brown, Maurizio Voi, Mace L. Rothenberg, Richard Schilsky, An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. ,vol. 85, pp. 1261- 1268 ,(1999) , 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T